Infectious Disease Diagnostics Market

Infectious disease diagnostic market by Type (Products [Instruments and Reagents & Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others), Technique (Polymerase chain reaction (PCR), Nucleic Acid Amplification Tests (NAAT), ELISA, Rapid immunochromatography assays, and Others), Application (Viral Diseases, Bacterial Diseases, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of infectious diseases and the rising product developmental activities worldwide.

The infectious disease diagnostics market was valued at USD 38.52 billion in 2023 and is estimated to grow at a CAGR of 3.80% during the forecast period from 2024 to 2030 to reach USD 48.10 billion by 2030. The infectious disease diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B & C, and influenza, the introduction of new and innovative products by key players, and others that are acting as major factors contributing to the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

Infectious Disease Diagnostics Market Dynamics:

As per the World Health Organization (WHO) 2024, nearly 39 million people were living with HIV infection in 2022, globally. The source also stated that nearly 37.5 million were adults (aged 15 and above) and approximately 1.5 million people were children, aged less than 15 years. Infectious disease diagnostics are crucial in identifying HIV infection, enabling early detection, treatment monitoring, and preventing transmission. Techniques such as molecular testing, antigen/antibody assays, and point-of-care tests are widely used to diagnose HIV, assess viral load, and guide therapy decisions.

Data from the WHO 2024, stated that 304 million people were infected by hepatitis B and C across the world in the year 2022. The same source further stated that out of these 254 million were afflicted by hepatitis B and 50 million were affected by hepatitis C. Infectious disease diagnostics enable early detection and treatment of hepatitis B and C through techniques like serology, nucleic acid testing, and rapid diagnostics, helping to control and prevent transmission.

Additionally, the introduction of new and innovative products by market players are pushing forward the market share for same. For example, in February 2023, Thermo Fisher introduced real-time PCR kits in India for the detection of infectious diseases. The Applied Biosystems TaqPath PCR kits are designed to provide confidence and reliability in diagnostic development and testing for conditions like Multi-Drug Resistant Tuberculosis (MDR-TB), M. Tuberculosis complex (MTB), Hepatitis B (HBV), Hepatitis C (HCV), HIV, and for genetic analysis such as HLA-B27.

Hence, the interplay of all the above-mentioned factors is expected to drive the market for infectious disease diagnostics during the given forecast period from 2024 to 2030.

However, the risk of sample contamination during transport and storage, among other factors may prove to be challenging factors for the growth of the infectious disease diagnostics market.

Infectious Disease Diagnostics Market Segment Analysis:

Infectious disease diagnostic market by Type (Products [Instruments and Reagents & Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others), Technique (Polymerase chain reaction (PCR), Nucleic Acid Amplification Tests (NAAT), ELISA, Rapid immunochromatography assays, and Others), Application (Viral Diseases, Bacterial Diseases, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the technology segment of the infectious disease diagnostics market, the immunoassays category is expected to have a significant revenue share in 2023. This is due to the various features and applications of immunoassays in diagnostics.

Immunoassay technology utilizes antibodies to identify and quantify pathogens, including viruses, bacteria, and other infectious agents. The key advantage of immunoassays is their sensitivity and specificity, which allow for the accurate detection of low levels of antigens or antibodies in patient samples. This is particularly valuable for early diagnosis and screening of diseases such as HIV, hepatitis, and influenza. Furthermore, immunoassays can be designed for high throughput, enabling the simultaneous testing of multiple samples, which is essential in outbreak situations. The technology also supports point-of-care testing, providing rapid results that facilitate timely clinical decision-making.

Additionally, in July 2023, Roche Diagnostics India announced the launch of the Elecsys® HCV Duo, India's first commercially available fully automated immunoassay. This assay enables the simultaneous and independent determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.

Therefore, the widespread uses of immunoassay in diagnostics, solidify the impact on the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall Infectious Disease Diagnostics Market:

Among all the regions, North America is estimated to hold a significant revenue share in the infectious disease diagnostics market. This domination is due to the growing burden of infectious diseases including tuberculosis, outbreaks of influenza, emerging pathogens, growing product developmental activities, presence of key manufacturers, among others that are expected to fuel the infectious disease diagnostics market in the region during forecast period from 2024 to 2030.

Public Health Agency of Canada (2024), stated that in 2022, there were 1,971 active tuberculosis cases in Canada. Infectious disease diagnostics is essential for the detection and identification of tuberculosis, utilizing techniques such as molecular testing, culture, and imaging. These methods facilitate prompt treatment, track disease transmission, and guide public health measures to manage outbreaks effectively.

Advancements in technology, such as the development of rapid diagnostic tests and molecular assays, enhance the accuracy and speed of diagnoses, making testing more accessible. The increase in point-of-care testing is also contributing to the market, allowing immediate results in clinical settings.

Rising product developmental activities by regulatory bodies in the region are likely to push forward the revenue shares for the same. For example, in November 2023, Abbott announced that it received the U.S. Food and Drug Administration (FDA) approval for its human papillomavirus or HPV screening solution.

Therefore, the interplay of all the factors mentioned above provide a conducive growth environment for the North America region in the infectious disease diagnostics market during the forecast period from 2024 to 2030.

Infectious Disease Diagnostics Market Key Players:

Some of the key market players operating in the infectious disease diagnostics market include BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Abbott, bioMérieux SA, QIAGEN, DiaSorin S.p.A, Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC., Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

Recent Developmental Activities in Infectious Disease Diagnostics Market:

•  
• In May 2024, Karius announced that its Karius Test, designed for diagnosing and managing lung infections in immunocompromised patients, received breakthrough device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
• In May 2022, BD announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.
• In December 2021, Roche announced the launch of the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.

Key Takeaways from the Infectious Disease Diagnostics Market Report Study

• Market size analysis for current infectious disease diagnostics market size (2023), and market forecast for 5 years (2024-2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global infectious disease diagnostics market.
• Various opportunities available for the other competitor in the infectious disease diagnostics market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current infectious disease diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for infectious disease diagnostics market growth in the coming future?

Target Audience who can be benefited from this Infectious Disease Diagnostics Market Report Study

• Infectious disease diagnostic products providers
• Research organizations and consulting companies
• Infectious disease diagnostic -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in infectious disease diagnostic
• Various end users want to know more about the infectious disease diagnostics market and the latest technological developments in the infectious disease diagnostics market.